<DOC>
	<DOCNO>NCT01250808</DOCNO>
	<brief_summary>Multiple Myeloma ( MM ) second diagnose malignancy hematological malignancy . The previous study point dosage course Bortezomib include dose concomitant drug use treatment MM patient get preferred treatment program , go determine optimal dos course Bortezomib prospective , multicenter clinical trial evaluate efficiency safety different program .</brief_summary>
	<brief_title>Technology Platform System Construction Clinical Evaluation Studies New Drugs Hematological Malignancy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Obtain informed consent form ( ICF ) sign patient relative . 2 . Patients newly diagnose multiple myeloma ( MM ) . ( Not include patient multiple solitary extramedullary plasmacytoma atⅠstage DurieSalmon stag system ) 3 . Measurable serum protein : IgG type MM : serum Mprotein≥ 1.0g/dl urine Mprotein≥ 200mg/24h . IgA type MM : serum Mprotein≥0.5g/dl urine Mprotein≥200mg/24h . IgM type MM : ( IgM Mprotein osteolytic lesion show Xray ) : serum protein≥ 1.0g/dl urine Mprotein≥ 200mg/24h . IgD type MM : serum Mprotein≥0.05g/dl urine Mprotein≥200mg/24h . Light chain type MM : serum Mprotein≥ 1.0g/dl urine Mprotein≥ 200mg/24h . 4 . Physical score 0~2 grade ( WHO standard ) , able comply visit time protocol requirement . 1 . Diagnosed relapsed multiple myeloma . 2 . Any serious disease may lead patient suffer unaccepted risk . 3 . Female patient pregnant breastfeeding . 4 . Histories malignant tumor MM , except patient whose disease cure least 3 year . Exception : basalcell carcinoma , squamous cell carcinoma , carcinoma situ uterine cervix , breast carcinoma situ , occasionally prostatic cancer histological discovery ( stage T1a T1B define TNM classification ) . 5 . Not able understand comply investigate protocol . 6 . Patients grade 2 high peripheral neuropathy treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>